Validation of a Model for Predicting Magnesium Concentration in Women with Preeclampsia: A Retrospective Cohort Study.

Autor: Holmström Thalme, Erik¹ (AUTHOR), Frödin-Bolling, Magnus² (AUTHOR)

Publikováno v: Journal of Pregnancy. 3/12/2024, Vol. 2024, p1-8. 8p.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Autor: Jaeger, Hans ^*, Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Andrade-Villanueva, Jaime Federico, Mngqibisa, Rosie, Hermida, Antonio Ocampo, Thalme, Anders, Belonosova, Elena, Ajana, Faïza, Benn, Paul D, Wang, Yuanyuan, Hudson, Krischan J, Español, Carlos Martín, Ford, Susan L, Crauwels, Herta, Margolis, David A, Talarico, Christine L, Smith, Kimberly Y, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Vanveggel, Simon, Spreen, William R

Publikováno v: In The Lancet HIV November 2021 8(11):e679-e689

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Autor: De Wit, S., Florence, E., Moutschen, M., Van Wijngaerden, E., Vandekerckhove, L., Vandercam, B., Brunetta, J., Conway, B., Klein, M., Murphy, D., Rachlis, A., Shafran, S., Walmsley, S., Ajana, F., Cotte, L., Girardy, P.-M., Katlama, C., Molina, J.-M., Poizot-Martin, I., Raffi, F., Rey, D., Reynes, J., Teicher, E., Yazdanpanah, Y., Gasiorowski, J., Halota, W., Horban, A., Piekarska, A., Witor, A., Arribas, J.R., Perez-Valero, I., Berenguer, J., Casado, J., Gatell, J.M., Gutierrez, F., Galindo, M.J., Gutierrez, M.D.M., Iribarren, J.A., Knobel, H., Negredo, E., Pineda, J.A., Podzamczer, D., Sogorb, J.Portilla, Pulido, F., Ricart, C., Rivero, A., Santos Gil, I., Blaxhult, A., Flamholc, L., Gisslèn, M., Thalme, A., Fehr, J., Rauch, A., Stoeckle, M., Clarke, A., Gazzard, B.G., Johnson, M.A., Orkin, C., Post, F., Ustianowski, A., Waters, L., Bailey, J., Benson, P., Bhatti, L., Brar, I., Bredeek, U.F., Brinson, C., Crofoot, G., Cunningham, D., DeJesus, E., Dietz, C., Dretler, R., Eron, J., Felizarta, F., Fichtenbaum, C., Gallant, J., Gathe, J., Hagins, D., Henn, S., Henry, W.K., Huhn, G., Jain, M., Lucasti, C., Martorell, C., McDonald, C., Mills, A., Morales-Ramirez, J., Mounzer, K., Nahass, R., Olivet, H., Osiyemi, O., Prelutsky, D., Ramgopal, M., Rashbaum, B., Richmond, G., Ruane, P., Scarsella, A., Scribner, A., Shalit, P., Shamblaw, D., Slim, J., Tashima, K., Voskuhl, G., Ward, D., Wilkin, A., de Vente, J., Eron, Joseph J., Orkin, Chloe, Cunningham, Douglas, Pulido, Federico, Post, Frank A., De Wit, Stéphane, Lathouwers, Erkki, Hufkens, Veerle, Jezorwski, John, Petrovic, Romana, Brown, Kimberley, Van Landuyt, Erika, Opsomer, Magda

Publikováno v: In Antiviral Research October 2019 170

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Autor: Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, de Vente, J, De Wit, S, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y, Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Gathe, Joseph, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Opsomer, Magda

Publikováno v: In The Lancet HIV January 2018 5(1):e23-e34

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Autor: Orkin, Chloe, DeJesus, Edwin, Ramgopal, Moti, Crofoot, Gordon, Ruane, Peter, LaMarca, Anthony, Mills, Anthony, Vandercam, Bernard, de Wet, Joseph, Rockstroh, Jürgen, Lazzarin, Adriano, Rijnders, Bart, Podzamczer, Daniel, Thalme, Anders, Stoeckle, Marcel, Porter, Danielle, Liu, Hui C, Cheng, Andrew, Quirk, Erin, SenGupta, Devi, Cao, Huyen

Publikováno v: In The Lancet HIV May 2017 4(5):e195-e204